Doxorubicin
Showing 1 - 25 of 2,767
Leiomyosarcoma Trial in Los Angeles (Lurbinectedin, Doxorubicin)
Recruiting
- Leiomyosarcoma
- Lurbinectedin
- Doxorubicin
-
Los Angeles, CaliforniaSarcoma Oncology Center
Oct 16, 2023
Advanced Soft-tissue Sarcoma Trial (LB-100 plus Doxorrubicin, Doxorubicin)
Not yet recruiting
- Advanced Soft-tissue Sarcoma
- LB-100 plus Doxorrubicin
- Doxorubicin
- (no location specified)
Apr 11, 2023
Cancer, Heart Failure, Arrhythmia Trial in Harbin (Control group:DH001 , Trial group: DH001 low-dose group, Trial group: DH001
Recruiting
- Cancer
- +4 more
- Control group:DH001 placebo
- +2 more
-
Harbin, Heilongjiang, ChinaHarbin Institute of Hematology and Cancer
Oct 20, 2023
Metastatic Leiomyosarcoma, Metastatic Sarcoma, Metastatic Soft Tissue Sarcoma Trial (Computed Tomography, Magnetic Resonance
Not yet recruiting
- Metastatic Leiomyosarcoma
- +5 more
- Computed Tomography
- +3 more
- (no location specified)
Feb 2, 2023
Cancer Trial (Empagliflozin 10 MG)
Not yet recruiting
- Cancer
- Empagliflozin 10 MG
- (no location specified)
Oct 22, 2023
Hepatocellular Carcinoma, Liver Cancer Trial in Seoul (IDA-TACE, DOX-TACE)
Recruiting
- Hepatocellular Carcinoma
- Liver Cancer
- IDA-TACE
- DOX-TACE
-
Seoul, Korea, Republic ofSeoul National University Hospital
Oct 27, 2023
Breast Cancer Stage 2 and 3 Trial (Fenofibrate, Placebo, Doxorubicin)
Not yet recruiting
- Breast Cancer Stage 2 and 3
- Fenofibrate
- +3 more
- (no location specified)
Nov 24, 2023
Breast Cancer With Liposomal Doxorubicin Regimen
Recruiting
- Breast Cancer
- +4 more
- Liposomal doxorubicin containing regimen
-
Hangzhou, Zhejiang, ChinaSecond Affiliate Hospital of Zhejiang University
Feb 7, 2023
Breast Cancer, Doxorubicin Induced Cardiotoxicity Trial in Damanhur (Placebo, Montelukast)
Recruiting
- Breast Cancer
- Doxorubicin Induced Cardiotoxicity
- Placebo
- Montelukast
-
Damanhūr, Elbehairah, EgyptDamanhour Oncology Center
Jul 16, 2023
Solid Tumor, KRAS Mutation-Related Tumors Trial in Washington (NEROFE, Doxorubicin)
Recruiting
- Solid Tumor
- KRAS Mutation-Related Tumors
- NEROFE
- Doxorubicin
-
Washington, District of ColumbiaGeorgetown Lombardi Comprehensive Cancer Center
Jan 23, 2023
Platinum-resistant Ovarian Cancer
Not yet recruiting
- Ovarian Cancer
- pegylated liposomal doxorubicin
- (no location specified)
Aug 2, 2023
Hodgkin Lymphoma Trial in Houston (Brentuximab vedotin, Doxorubicin Hydrochloride, Pembrolizumab)
Not yet recruiting
- Hodgkin Lymphoma
- Brentuximab vedotin
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jun 20, 2023
Metastatic Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma Trial in Hannover (Durvalumab and Tremelimumab,
Completed
- Metastatic Adult Soft Tissue Sarcoma
- Recurrent Adult Soft Tissue Sarcoma
- Durvalumab and Tremelimumab
- Doxorubicin
-
Hannover, GermanyMedizinische Hochschule Hannover
Jan 18, 2023
Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma Trial in Aurora (doxorubicin with AGEN1884 and AGEN2034)
Recruiting
- Metastatic Soft Tissue Sarcoma
- Advanced Soft Tissue Sarcoma
- doxorubicin with AGEN1884 and AGEN2034
-
Aurora, ColoradoUniversity of Colorado Hospital
Jan 4, 2023
Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma
Active, not recruiting
- Soft Tissue Sarcoma
- Doxil
- Doxorubicin
-
Philadelphia, PennsylvaniaFox Chase Cancer Center
Jan 25, 2023
Large B-Cell Lymphoma Trial in Xi'an (Glofitamab, Polatuzumab vedotin, Rituximab)
Not yet recruiting
- Large B-Cell Lymphoma
- Glofitamab
- +5 more
-
Xi'an, ChinaFirst Affiliated Hospital of Medical College of Xi'an Jiaotong U
Sep 14, 2023
Kaposi Sarcoma, HIV-1-infection Trial (Pegylated liposomal doxorubicin, Paclitaxel)
Not yet recruiting
- Kaposi Sarcoma
- HIV-1-infection
- Pegylated liposomal doxorubicin
- Paclitaxel
- (no location specified)
Jan 20, 2023
Mitochondrial dysfUnction:Key Player in Doxorubicin-induced
Not yet recruiting
- Doxorubicin Induced Cardiomyopathy
- +3 more
- 31-MRS at 7 Tesla (T)
-
Utrecht, Netherlands
- +1 more
Feb 7, 2023
Metastatic Kidney Medullary Carcinoma, Metastatic Renal Cell Carcinoma, SMARCB1 Negative Trial in Houston (Doxorubicin,
Recruiting
- Metastatic Kidney Medullary Carcinoma
- +4 more
- Doxorubicin
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Jan 20, 2023
Cutaneous Squamous Cell Carcinoma, Skin Cancers - Squamous Cell Carcinoma Trial in Pittsburgh (Microneedle Array Doxorubicin
Not yet recruiting
- Cutaneous Squamous Cell Carcinoma
- Skin Cancers - Squamous Cell Carcinoma
- Microneedle Array Doxorubicin (MNA-D)
-
Pittsburgh, PennsylvaniaUniversity of Pittsburgh Medical Center
Nov 28, 2022
Breast Cancer Trial in Shanghai (Pegylated liposomal doxorubicin, Epirubicin, Cyclophosphamid)
Recruiting
- Breast Cancer
- Pegylated liposomal doxorubicin
- +5 more
-
Shanghai, ChinaShanghai Pudong Hospital
Dec 11, 2022
Brain Tumor Trial in Washington (Exablate, Doxorubicin)
Recruiting
- Brain Tumor
- Exablate
- Doxorubicin
-
Washington, District of ColumbiaChildren's National Medical Center
Jan 4, 2023
Brain Tumor Trial in Toronto (Exablate, Doxorubicin)
Recruiting
- Brain Tumor
- Exablate
- Doxorubicin
-
Toronto, Ontario, CanadaSunnybrook Research Institute
Jan 5, 2023
High-Risk Localized Soft Tissue Sarcoma Trial in Shanghai (Pegylated Liposomal Doxorubicin, Doxorubicin, Anti-PD-1 mAb)
Recruiting
- High-Risk Localized Soft Tissue Sarcoma
- Pegylated Liposomal Doxorubicin
- +3 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 15, 2023
Advanced Sarcoma, Metastatic Sarcoma, Soft Tissue Sarcoma Trial (YH001, Envafolimab, Doxorubicin)
Recruiting
- Advanced Sarcoma
- +2 more
- YH001
- +2 more
-
Santa Monica, CaliforniaSarcoma Oncology Center
Dec 5, 2022